ArticleClinical and translational radiation oncology2026
Feasibility of dose accumulation for assessing treatment-related side effects in MR-guided abdominal SABR: A single-institution study.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Daily adaptive magnetic resonance (MR)-guided treatment changes delivered dose distributions, making cumulative dose uncertain. This work assessed the feasibility of exploring potential relationships between side effects and accumulated dose (AD) in MR-guided stereotactic ablative radiotherapy (SABR) for liver and pancreatic cancers. Using deformable image registration (DIR), AD to abdominal organs at risk (OARs) were estimated and potential relationships with observed side effects explored. Methods: Forty-one patients treated with 5-fraction MR-guided SABR to primary or metastatic pancreatic and liver tumours were retrospectively included. Daily adapted plans were deformably mapped and summed to estimate AD. Differences between accumulated and planned dose were assessed. Changes in clinician-reported symptoms collected at baseline, 3, and 6 months were analysed. Associations between AD and symptoms were assessed using Spearman's rank test. Results: Most AD metrics were lower than planned for gastrointestinal OARs, reflecting potential differences from delivered ATS plans, with significant reductions in duodenum and large bowel D0.5cc and D10cc ( Conclusion: Exploring potential relationships between DIR-based accumulated OAR dose and side effects was feasible. Preliminary relationships between accumulated OAR dose and side effects were observed; however, further work in larger studies is warranted before these findings can be used to personalise treatment in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.